Sign In
Buy CELU
$1.06
-0.0100 (-0.93%)
At Close: Jun 02, 2026
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
09:15am, Tuesday, 14'th May 2024
Placental T Cells Demonstrated Greater Persistence, Resistance to Exhaustion and Efficacy Compared To Peripheral Blood Mononuclear Cells Placental T Cells Demonstrated Greater Persistence, Resistance
Celularity Inc. to Host Investor and Analyst Research & Development Day
08:00am, Monday, 22'nd Apr 2024
Event Will Be Hosted On-site and Aired Virtually Highlighting Research, Clinical and Commercial Progress Event Will Be Hosted On-site and Aired Virtually Highlighting Research, Clinical and Commerci
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
05:30pm, Friday, 19'th Apr 2024
FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and
FLORHAM PARK, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and adv
CELU Announces Net Sales Trending Ahead of Expectations for 1Q '24; Implements Planned '24 SG&A Reductions & Mfg. Ramp for Advanced Biomaterial Products
FLORHAM PARK, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and advanced
Nationally Established Q Code Will Further Support the Use of Biovance® 3L by Physicians to Treat Wound Care Patients in Office Settings Nationally Established Q Code Will Further Support the Use of
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
09:15am, Wednesday, 20'th Mar 2024
Company Has Already Received IND Clearance from the FDA and Plans to Begin Phase 1/2 Study in 2024 with Off-the-Shelf, Placental-Derived Cell Therapy Company Has Already Received IND Clearance from th
Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit
09:15am, Thursday, 14'th Mar 2024
Presentation Will Discuss Cellular Immunotherapy's Potential Role in Treating Chronic Conditions and Extending People's Lives Presentation Will Discuss Cellular Immunotherapy's Potential Role in Treat
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
09:20am, Tuesday, 12'th Mar 2024
Keynote Will Discuss Cellular Immunotherapy's Potential for Treating Chronic Conditions, Including Cancer, Multiple Sclerosis and Parkinson's Disease Keynote Will Discuss Cellular Immunotherapy's Pote
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells
09:35am, Thursday, 07'th Mar 2024
Company presenting an in vivo study of PT-CD16, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells at AACR Annual Meeting 2024 Company presenting an
Celularity Announces 1-for-10 Reverse Stock Split
04:10pm, Friday, 23'rd Feb 2024
FLORHAM PARK, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Celularity, Inc. (Nasdaq: CELU; CELUW) (“Celularity”), a biotechnology company developing allogeneic cell therapies and advanced biomaterial p
-Highlights potential uses of Celularity biomaterials in regenerative medicine applications that combine stem cells and biomaterial scaffolds for use in constructing tissues and for cell delivery
Continuing the substantial growth trajectory that began during 2023, for the first quarter 2024 and the full year 2024, Celularity expects triple-digit percentage increases in combined net sales of i
Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions
09:00am, Thursday, 25'th Jan 2024
Celularity closed two financing transactions on January 16, 2024, totaling $21 million in gross proceeds, consisting of a $6 million private placement with its largest investor, Dragasac Limited, and
